Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Prostate Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
Conditions
Brief summary
This phase I trial studies the side effects and best dose of PI3Kbeta inhibitor AZD8186 when given together with docetaxel in treating patients with solid tumors with PTEN or PIK3CB mutations that have spread to other places in the body (metastatic) or cannot be removed by surgery. PI3Kbeta inhibitor AZD8186 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving PI3Kbeta inhibitor AZD8186 and docetaxel may work better in treating patients with solid tumors.
Detailed description
PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of PI3Kbeta inhibitor AZD8186 (AZD8186) when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors. II. To assess the safety and tolerability of AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors. SECONDARY OBJECTIVES: I. To observe and record anti-tumor activity. Ia. To assess the objective response rate (ORR) of AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors. Ib. To assess the clinical benefit rate at 24 weeks of AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors. II. To investigate a drug-drug interaction between docetaxel and AZD8186 and correlate drug exposure with pharmacodynamics response. EXPLORATORY OBJECTIVES: I. Examine the pattern of co-mutated genes in PTEN or PIK3CB mutated tumors and their association with treatment response or resistance. II. Describe possible mechanisms of acquired resistance to PI3Kbeta inhibition. III. Evaluation of protein expression of the PTEN gene and its association with treatment response or resistance. IV. Examine isoform-specific AKT inhibition and other downstream target modulation from PI3Kbeta inhibition with AZD8186. OUTLINE: This is a dose-escalation study of PI3Kbeta inhibitor AZD8186. Patients receive docetaxel intravenously (IV) over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 orally (PO) twice daily (BID) for 5 days each week. Cycles repeat every 21 days until April 30, 2022 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days and then every 3 months.
Interventions
Given IV
Correlative studies
Correlative studies
Given PO
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective * Patients must be able to swallow and retain oral medications and be without gastrointestinal illnesses that would preclude absorption of AZD8186 * Unlimited prior therapies allowed * Docetaxel appropriate * Patients who have not received prior docetaxel (or other taxane therapy) in the advanced setting are eligible for all cohorts * Patients who have previously received docetaxel (or other taxane therapy) in the advanced setting are eligible for the dose escalation cohort only, if anticipated to have maintained taxane sensitivity and in the opinion of the investigator would still benefit from further docetaxel therapy * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Hemoglobin \>= 8 g/L * Platelets \>= 100,000/mcL * Total bilirubin within normal institutional limits * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 1.5 x institutional upper limit of normal * Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * PTEN or PIK3CB mutated advanced solid tumor * PTEN loss of function mutation or PIK3CB gain of function mutation identified by local Clinical Laboratory Improvement Act (CLIA) certified next generation sequencing (NGS) * Breast cancers patients enrolled on this study must have either: * Estrogen receptor positive and HER2 negative breast cancer * Triple negative breast cancer * Adequate archival tissue (metastatic tissue sample is preferable but primary tumor tissue will be acceptable) or willing to undergo pre-treatment biopsy (for central confirmation of molecular alteration and PTEN immunohistochemical assessment) if adequate archival tissue is unavailable * The effects of AZD8186 on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of AZD8186 administration * Ability to understand and the willingness to sign a written informed consent document * DOSE ESCALATION COHORT: Prior receipt of docetaxel is permitted * DOSE ESCALATION COHORT: Measurable disease is not required for enrollment * PHARMACODYNAMIC EXPANSION COHORT: Prior receipt of docetaxel is not permitted * PHARMACODYNAMIC EXPANSION COHORT: Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>= 20 mm (\>= 2 cm) by chest x-ray or as \>= 10 mm (\>= 1 cm) with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam * PHARMACODYNAMIC EXPANSION COHORT: Consent to allow mandatory paired (pre- and on- treatment) fresh tissue biopsies if deemed safe to do so for quantitation of Akt pathway signaling proteins * DISEASE SPECIFIC EXPANSION COHORTS: Prior receipt of docetaxel is not permitted * DISEASE SPECIFIC EXPANSION COHORTS: Patients (excepting the prostate cancer patients) must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>= 20 mm (\>= 2 cm) by chest x-ray or as \>= 10 mm (\>= 1 cm) with CT scan, MRI, or calipers by clinical exam * DISEASE SPECIFIC EXPANSION COHORTS: Breast cancers patients enrolled on this study must have: * Metastatic or advanced (incurable and unresectable) HER2 negative breast cancer regardless of estrogen receptor status (both hormone receptor positive and triple negative patients are eligible) * Received hormonal therapy, as appropriate based on their hormone receptor status; hormone receptor positive patients who have not received endocrine therapy for recurrent/metastatic disease are eligible, permitted their physician feels they are not appropriate for first line endocrine therapy, for example for high risk visceral metastatic disease * DISEASE SPECIFIC EXPANSION COHORTS: Prostate cancers patients enrolled on this study (applies to all prostate cancer patients treated on parts 1, 2, and 3) must have: * Metastatic or advanced (incurable and unresectable) castration resistant metastatic cancer * Received at least one additional line of anti-androgen therapy with abiraterone or enzalutamide * Measurable disease is not required for enrollment
Exclusion criteria
* HER2 positive breast cancer * Prior treatment with PI3K/AKT inhibitors * Any known concurrent RAF or PIK3CA mutation * Patients who have had chemotherapy, radiotherapy, immunotherapy or anticancer agents within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of the first dose of study treatment, except hormonal therapy with luteinizing hormone-releasing hormone (LHRH) analogues for medical castration in patients with prostate cancer and breast cancer, which are permitted * Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) * Patients who are receiving any other investigational agents * Patients with known, untreated or unstable brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; patients with treated brain metastases are eligible if the metastases have been radiographically and clinically stable for at least one month; if on steroids for this indication, the patient must be on a stable dose for at least one month * History of clinically significant allergic reactions attributed to compounds of similar chemical or biologic composition to AZD8186 or docetaxel or to docetaxel itself * Patients receiving any medications or substances that are strong inhibitors and/or strong or moderate inducers of CYP3A4 are ineligible; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product * Existing bleeding or condition associated with increased risk of bleeding * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study because AZD8186 is a PI3K inhibitor with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AZD8186, breastfeeding should be discontinued if the mother is treated with AZD8186; these potential risks may also apply to other agents used in this study * Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have: * A stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong inhibitors and strong or moderate inducers of CYP3A4 * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Dose Limiting Toxicity (DLT) | At Day 22 | The number of DLTs at each dose level will determine the MTD or RP2D of PI3Kbeta inhibitor AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors. |
| Number of Participants With Adverse Events (AEs) Grades 3-5 | Up to 3 years | Patient safety and tolerability will be described according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version for routine toxicity reporting and CTCAE, version 5 for serious adverse events only. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | At 24 weeks | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR. For participants with prostate cancer who do not have sites of disease on imaging, objective response is the reduction of prostate specific antigen (PSA) level of 50% or more. |
| Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | At 24 weeks | Will be assessed by modified Response Evaluation Criteria in Solid Tumors version 1.1. Will assess the CBR of PI3Kbeta inhibitor AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors. A 90% confidence interval on CBR will be calculated assuming binomial proportions. |
| Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | Up to 6 hours after initial treatment | Will investigate the concentration of docetaxel in the blood when participants also take the PI3Kbeta inhibitor AZD8186. Blood is drawn after docetaxel infusion and before the participant takes AZD8186, after the participant takes AZD8186, and again 6 hours after taking AZD8186. Blood concentrations of docetaxel are measured at each collection time. The change in concentrations at the different dose levels may suggest whether AZD8186 impacts how much docetaxel is still in the blood over time. |
Countries
United States
Contacts
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose Level 1 Patients receive docetaxel 75 mg/m\^2 IV over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 60 mg PO BID for 5 days each week. Cycles repeat every 21 days until April 30, 2022 in the absence of disease progression or unacceptable toxicity. | 6 |
| Dose Level -1 Patients receive docetaxel 75 mg/m\^2 IV over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 30 mg PO BID for 5 days each week. Cycles repeat every 21 days until April 30, 2022 in the absence of disease progression or unacceptable toxicity. | 1 |
| Dose Level -1B Patients receive docetaxel 60 mg/m\^2 IV over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 60 mg PO BID for 5 days each week. Cycles repeat every 21 days until April 30, 2022 in the absence of disease progression or unacceptable toxicity. | 5 |
| Dose Level 1 With Growth Factors Patients receive docetaxel 75 mg/m\^2 IV over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 60 mg PO BID for 5 days each week. Cycles repeat every 21 days until April 30, 2022 in the absence of disease progression or unacceptable toxicity. | 4 |
| Dose Level 2 Patients receive docetaxel 75 mg/m\^2 IV over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 120 mg PO BID for 5 days each week. Cycles repeat every 21 days until April 30, 2022 in the absence of disease progression or unacceptable toxicity. | 7 |
| Total | 23 |
Baseline characteristics
| Characteristic | Dose Level 1 | Total | Dose Level 2 | Dose Level 1 With Growth Factors | Dose Level -1B | Dose Level -1 |
|---|---|---|---|---|---|---|
| Age, Continuous | 50 years | 56 years | 61 years | 56 years | 55 years | 56 years |
| Body Surface Area | 1.86 meters squared (m^2) | 1.90 meters squared (m^2) | 1.94 meters squared (m^2) | 1.73 meters squared (m^2) | 1.68 meters squared (m^2) | 2.22 meters squared (m^2) |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 4 Participants | 20 Participants | 7 Participants | 4 Participants | 4 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Height | 168.5 centimeter (cm) | 168 centimeter (cm) | 170 centimeter (cm) | 160.5 centimeter (cm) | 170 centimeter (cm) | 183 centimeter (cm) |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 5 Participants | 21 Participants | 7 Participants | 3 Participants | 5 Participants | 1 Participants |
| Region of Enrollment United States | 6 participants | 23 participants | 7 participants | 4 participants | 5 participants | 1 participants |
| Sex: Female, Male Female | 4 Participants | 16 Participants | 3 Participants | 4 Participants | 4 Participants | 1 Participants |
| Sex: Female, Male Male | 2 Participants | 7 Participants | 4 Participants | 0 Participants | 1 Participants | 0 Participants |
| Weight | 79.5 kilogram (kg) | 76.2 kilogram (kg) | 77.9 kilogram (kg) | 68 kilogram (kg) | 58.6 kilogram (kg) | 100 kilogram (kg) |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 4 / 6 | 1 / 1 | 3 / 5 | 2 / 4 | 2 / 7 |
| other Total, other adverse events | 6 / 6 | 1 / 1 | 5 / 5 | 4 / 4 | 7 / 7 |
| serious Total, serious adverse events | 4 / 6 | 1 / 1 | 4 / 5 | 1 / 4 | 3 / 7 |
Outcome results
Number of Participants With Adverse Events (AEs) Grades 3-5
Patient safety and tolerability will be described according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version for routine toxicity reporting and CTCAE, version 5 for serious adverse events only.
Time frame: Up to 3 years
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dose Level 1 | Number of Participants With Adverse Events (AEs) Grades 3-5 | Experienced AEs grades 3-5 | 4 Participants |
| Dose Level 1 | Number of Participants With Adverse Events (AEs) Grades 3-5 | Not Experienced AEs grades 3-5 | 1 Participants |
| Dose Level -1 | Number of Participants With Adverse Events (AEs) Grades 3-5 | Not Experienced AEs grades 3-5 | 0 Participants |
| Dose Level -1 | Number of Participants With Adverse Events (AEs) Grades 3-5 | Experienced AEs grades 3-5 | 1 Participants |
| Dose Level -1B | Number of Participants With Adverse Events (AEs) Grades 3-5 | Experienced AEs grades 3-5 | 3 Participants |
| Dose Level -1B | Number of Participants With Adverse Events (AEs) Grades 3-5 | Not Experienced AEs grades 3-5 | 0 Participants |
| Dose Level 1 With Growth Factors | Number of Participants With Adverse Events (AEs) Grades 3-5 | Not Experienced AEs grades 3-5 | 2 Participants |
| Dose Level 1 With Growth Factors | Number of Participants With Adverse Events (AEs) Grades 3-5 | Experienced AEs grades 3-5 | 1 Participants |
| Dose Level 2 | Number of Participants With Adverse Events (AEs) Grades 3-5 | Not Experienced AEs grades 3-5 | 2 Participants |
| Dose Level 2 | Number of Participants With Adverse Events (AEs) Grades 3-5 | Experienced AEs grades 3-5 | 4 Participants |
Number of Participants With Dose Limiting Toxicity (DLT)
The number of DLTs at each dose level will determine the MTD or RP2D of PI3Kbeta inhibitor AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors.
Time frame: At Day 22
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dose Level 1 | Number of Participants With Dose Limiting Toxicity (DLT) | Experienced Dose Limiting Toxicity | 2 Participants |
| Dose Level 1 | Number of Participants With Dose Limiting Toxicity (DLT) | Did not experience Dose Limiting Toxicity | 3 Participants |
| Dose Level -1 | Number of Participants With Dose Limiting Toxicity (DLT) | Experienced Dose Limiting Toxicity | 0 Participants |
| Dose Level -1 | Number of Participants With Dose Limiting Toxicity (DLT) | Did not experience Dose Limiting Toxicity | 1 Participants |
| Dose Level -1B | Number of Participants With Dose Limiting Toxicity (DLT) | Experienced Dose Limiting Toxicity | 0 Participants |
| Dose Level -1B | Number of Participants With Dose Limiting Toxicity (DLT) | Did not experience Dose Limiting Toxicity | 3 Participants |
| Dose Level 1 With Growth Factors | Number of Participants With Dose Limiting Toxicity (DLT) | Did not experience Dose Limiting Toxicity | 3 Participants |
| Dose Level 1 With Growth Factors | Number of Participants With Dose Limiting Toxicity (DLT) | Experienced Dose Limiting Toxicity | 0 Participants |
| Dose Level 2 | Number of Participants With Dose Limiting Toxicity (DLT) | Experienced Dose Limiting Toxicity | 0 Participants |
| Dose Level 2 | Number of Participants With Dose Limiting Toxicity (DLT) | Did not experience Dose Limiting Toxicity | 6 Participants |
Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease
Will be assessed by modified Response Evaluation Criteria in Solid Tumors version 1.1. Will assess the CBR of PI3Kbeta inhibitor AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors. A 90% confidence interval on CBR will be calculated assuming binomial proportions.
Time frame: At 24 weeks
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dose Level 1 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Not assessed | 0 Participants |
| Dose Level 1 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Complete Response (CR) | 0 Participants |
| Dose Level 1 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Stable Disease (SD) | 1 Participants |
| Dose Level 1 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Progressive Disease (PD) | 4 Participants |
| Dose Level 1 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Partial Response (PR) | 0 Participants |
| Dose Level -1 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Partial Response (PR) | 0 Participants |
| Dose Level -1 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Progressive Disease (PD) | 0 Participants |
| Dose Level -1 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Complete Response (CR) | 0 Participants |
| Dose Level -1 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Stable Disease (SD) | 0 Participants |
| Dose Level -1 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Not assessed | 1 Participants |
| Dose Level -1B | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Not assessed | 0 Participants |
| Dose Level -1B | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Progressive Disease (PD) | 2 Participants |
| Dose Level -1B | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Partial Response (PR) | 1 Participants |
| Dose Level -1B | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Stable Disease (SD) | 0 Participants |
| Dose Level -1B | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Complete Response (CR) | 0 Participants |
| Dose Level 1 With Growth Factors | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Complete Response (CR) | 0 Participants |
| Dose Level 1 With Growth Factors | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Progressive Disease (PD) | 2 Participants |
| Dose Level 1 With Growth Factors | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Partial Response (PR) | 0 Participants |
| Dose Level 1 With Growth Factors | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Not assessed | 1 Participants |
| Dose Level 1 With Growth Factors | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Stable Disease (SD) | 0 Participants |
| Dose Level 2 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Stable Disease (SD) | 1 Participants |
| Dose Level 2 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Not assessed | 1 Participants |
| Dose Level 2 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Partial Response (PR) | 0 Participants |
| Dose Level 2 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Progressive Disease (PD) | 4 Participants |
| Dose Level 2 | Clinical Benefit Rate (CBR) Defined as Complete Response (CR), Partial Response (PR), or Stable Disease | Complete Response (CR) | 0 Participants |
Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186
Will investigate the concentration of docetaxel in the blood when participants also take the PI3Kbeta inhibitor AZD8186. Blood is drawn after docetaxel infusion and before the participant takes AZD8186, after the participant takes AZD8186, and again 6 hours after taking AZD8186. Blood concentrations of docetaxel are measured at each collection time. The change in concentrations at the different dose levels may suggest whether AZD8186 impacts how much docetaxel is still in the blood over time.
Time frame: Up to 6 hours after initial treatment
Population: Test not collected for pts on dose level -1.
| Arm | Measure | Group | Value (MEDIAN) | Dispersion |
|---|---|---|---|---|
| Dose Level 1 | Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | 6 Hours after Treatment | 6213.8 ng/ml | Standard Deviation 3991.4 |
| Dose Level 1 | Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | Pre-Treatment | 3083.3 ng/ml | Standard Deviation 1933.8 |
| Dose Level 1 | Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | After Treatment | 6981.7 ng/ml | Standard Deviation 4457.9 |
| Dose Level -1B | Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | 6 Hours after Treatment | 3056.1 ng/ml | Standard Deviation 0 |
| Dose Level -1B | Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | After Treatment | 3615.0 ng/ml | Standard Deviation 0 |
| Dose Level -1B | Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | Pre-Treatment | 2060.0 ng/ml | Standard Deviation 0 |
| Dose Level 1 With Growth Factors | Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | Pre-Treatment | 3280.0 ng/ml | Standard Deviation 585.1 |
| Dose Level 1 With Growth Factors | Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | After Treatment | 4728.6 ng/ml | Standard Deviation 0 |
| Dose Level 1 With Growth Factors | Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | 6 Hours after Treatment | 4411.6 ng/ml | Standard Deviation 0 |
| Dose Level 2 | Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | 6 Hours after Treatment | 7008.0 ng/ml | Standard Deviation 3877 |
| Dose Level 2 | Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | Pre-Treatment | 3450.0 ng/ml | Standard Deviation 1735.9 |
| Dose Level 2 | Maximum Blood Concentrations of Docetaxel When Also Taking AZD8186 | After Treatment | 6493.9 ng/ml | Standard Deviation 3437.8 |
Objective Response Rate (ORR)
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR. For participants with prostate cancer who do not have sites of disease on imaging, objective response is the reduction of prostate specific antigen (PSA) level of 50% or more.
Time frame: At 24 weeks
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dose Level 1 | Objective Response Rate (ORR) | Objective response | 0 Participants |
| Dose Level 1 | Objective Response Rate (ORR) | Not assessed | 0 Participants |
| Dose Level 1 | Objective Response Rate (ORR) | No objective response | 5 Participants |
| Dose Level -1 | Objective Response Rate (ORR) | No objective response | 0 Participants |
| Dose Level -1 | Objective Response Rate (ORR) | Objective response | 0 Participants |
| Dose Level -1 | Objective Response Rate (ORR) | Not assessed | 1 Participants |
| Dose Level -1B | Objective Response Rate (ORR) | No objective response | 2 Participants |
| Dose Level -1B | Objective Response Rate (ORR) | Objective response | 1 Participants |
| Dose Level -1B | Objective Response Rate (ORR) | Not assessed | 0 Participants |
| Dose Level 1 With Growth Factors | Objective Response Rate (ORR) | Objective response | 0 Participants |
| Dose Level 1 With Growth Factors | Objective Response Rate (ORR) | Not assessed | 1 Participants |
| Dose Level 1 With Growth Factors | Objective Response Rate (ORR) | No objective response | 2 Participants |
| Dose Level 2 | Objective Response Rate (ORR) | No objective response | 5 Participants |
| Dose Level 2 | Objective Response Rate (ORR) | Objective response | 0 Participants |
| Dose Level 2 | Objective Response Rate (ORR) | Not assessed | 1 Participants |